A Phase 3 interventional study of Ketamine Hydrochloride and Midazolam Hydrochloride in Suicide, Attempted, Suicide and Depression and Suicide Threat, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.
Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 100th largest by enrollment of the 140 interventional ones that give a count, is one of 17 that started in 2022, is one of 3 in phase 3, and was the 66th registered.
281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.
Browse Suicide, Attempted studies →53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 12+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 13–17
University of Michigan · Sites in United States
Ages 18–65
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 6 · Phase 4 3
First in 1999; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 129 across 224 interventional studies indexed under Suicide, Attempted.
Median enrollment 117 across the 140 interventional studies, 225 across the 7 observational. Of the 87 that completed or were terminated, 30 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 149 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 8 studies filed under Suicide, Attempted — fewer than ten, so there is no comparison to draw.
30 of the studies in Suicide, Attempted with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04763343Phase 3Tatiana Falcone, MDKetamine Treatment of Youth Suicide Attempters | 2027-02-28 |
| NCT07170657University of Texas Southwestern Medical CenterTeen Recovery Through Inspiration, Support, and Empowerment | 2026-11 |
| NCT06460220Jennifer HughesSAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth | 2026-12 |
| NCT06285708Ohio State UniversityEnhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD | 2026-12 |
| NCT04578938Rebecca PriceKetamine + Cognitive Training for Suicidality in the Medical Setting | 2026-12-02 |
Add all 30 to your calendar (.ics) → With an account.
Among the 149 studies in Suicide, Attempted with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to examine the signal of efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks.
The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.
Adolescent patients (ages 13-18) who have recent suicidality (defined as suicide attempt or urgent evaluation for a suicidal ideation or behavior), and who are receiving standard of care treatment (e.g., psychosocial and/or psychopharmacological treatment) will be recruited for participation in the study. Upon informed consent/assent, screening data will be collected regarding mood symptoms, suicidal ideation and behavior, associated comorbidities, and treatment history. Youth participants will be randomized to receive infusions of either ketamine or midazolam, which will be provided twice weekly for two weeks. Participants will then have follow-up assessments visits through week 12 to continue to monitoring outcome measures.
Participants may be recruited directly from their standard care outpatient provider, SPARC Intensive Outpatient Program (IOP) located at Children's Health Medical Center, from the Children's Health Emergency Department (ED) or inpatient psychiatric unit located at the Dallas campus. Participants may also be recruited into the study even if they are seen in the in emergency departments or inpatient hospitalization outside of University of Texas (UT) Southwestern and Children's Health Medical Center. Recruitment and consent procedures may begin during ED or inpatient hospitalization; however, as the study is an outpatient study, study procedures will not begin until the participant is discharged from the ED or inpatient hospital.
Recruitment efforts will target medically healthy male and female youths with recent suicide events who are either seeking care at an emergency room, admitted to an inpatient unit, enrolled in an IOP, or receiving adequate outpatient care with either psychopharmacological or psychosocial treatment following a suicide event.
Enrollment of 114 subjects is expected to take place over a period of approximately 36 months. Enrolled participants will be involved in the study for approximately 14 weeks. Visits include a Screening Visit, 4 Study Intervention Visits, and 11 Follow-Up Visits (combination of in-person and remote visits). Multiple streams of outcome measures will be utilized for this protocol, including self-report measures, research assessor-completed measures, clinic level measures, and behavioral measures.
Aim 1. Evaluate reduction in repeat suicidal events with ketamine.
Aim 2. Evaluate reduction in implicit suicidal cognition with ketamine.
Aim 3. Evaluate reduction in depressive symptoms and suicidality with ketamine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participants must:
Exclusion Criteria
Study participants must not:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
Drug: Ketamine Hydrochloride · Drug: Midazolam Hydrochloride
0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
Drug: Ketamine Hydrochloride · Drug: Midazolam Hydrochloride
infused over a 40 minute period
Also known as: Ketalar
infused over a 40 minute period
Also known as: Versed
Number of Days to First Suicidal Event
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
Time frame: 12 weeks
Number of Days to First Suicidal Event (by Sex)
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
Time frame: 12 weeks
Number of Days to First Suicidal Event (by Ethnicity)
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
Time frame: 12 weeks
Number of Days to First Suicidal Event (by Race)
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
Time frame: 12 weeks
Death/Suicide Implicit Association Test (IAT) Score
The Death/Suicide Implicit Association Test (IAT) is computerized reaction-time test designed to measure implicit associations between the self and death. Participants categorize stimuli representing 1) self versus non-self, and 2) death versus life concepts. Based on response latencies across task conditions, a score is computed. Positive scores represent faster response time on association between death and self, while negative scores represent stronger associations between life and self. Thus, higher scores indicate a worse outcome. The scale is based on reaction times so there is not a fixed range.
Time frame: 2 weeks
Concise Health Risk Tracking Self-Report (CHRT-SR) Score
Concise Health Risk Tracking Self-Report (CHRT-SR) consists of 14 questions with responses ranging from 0 (strongly disagree) to 4 (strongly agree). A total score is calculated by the sum of all 14 responses, with a total ranging from 0 to 56. A higher score indicates a greater risk for suicide.
Time frame: 2 weeks
Percentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure
Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C). consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. a yes on any of the 9 questions indicates presence of suicidal event/behaviors (ideation, attempt, preparatory acts, non suicidal self injury, other injury).
Time frame: 2 week
Inventory of Depressive Symptomatology (IDS) Self Report Score
The Inventory of Depressive Symptomatology (IDS) Self Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD. The self-report (IDS-SR) consists of 30 questions with a total score of 0 to 84. A higher score indicates a higher level of depressive symptom severity. The self report (IDS-SR) will be completed at each visit.
Time frame: 2 weeks
| Milestone | Ketamine | Midazolam |
|---|---|---|
| Started | 28 | 22 |
| Completed | 26 | 21 |
| Not completed | 2 | 1 |
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
| Days to event | Ketamine | Midazolam |
|---|---|---|
| Number of Days to First Suicidal Event | 75.86 ± 3.6 | 35.59 ± 1.6 |
The Death/Suicide Implicit Association Test (IAT) is computerized reaction-time test designed to measure implicit associations between the self and death. Participants categorize stimuli representing 1) self versus non-self, and 2) death versus life concepts. Based on response latencies across task conditions, a score is computed. Positive scores represent faster response time on association between death and self, while negative scores represent stronger associations between life and self. Thus, higher scores indicate a worse outcome. The scale is based on reaction times so there is not a fixed range.
| score on a scale | Ketamine | Midazolam |
|---|---|---|
| Death/Suicide Implicit Association Test (IAT) Score | .212 ± .06 | .80 ± .08 |
Concise Health Risk Tracking Self-Report (CHRT-SR) consists of 14 questions with responses ranging from 0 (strongly disagree) to 4 (strongly agree). A total score is calculated by the sum of all 14 responses, with a total ranging from 0 to 56. A higher score indicates a greater risk for suicide.
| score on a scale | Ketamine | Midazolam |
|---|---|---|
| Concise Health Risk Tracking Self-Report (CHRT-SR) Score | 19.26 ± 2.1 | 18.42 ± 2.3 |
Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C). consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. a yes on any of the 9 questions indicates presence of suicidal event/behaviors (ideation, attempt, preparatory acts, non suicidal self injury, other injury).
| percentage of subjects | Ketamine | Midazolam |
|---|---|---|
| Percentage of Participants With Suicidal Events/Behaviors as Measured by CHRT-C a Self Report Measure | 89.30 | 68.20 |
The Inventory of Depressive Symptomatology (IDS) Self Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD. The self-report (IDS-SR) consists of 30 questions with a total score of 0 to 84. A higher score indicates a higher level of depressive symptom severity. The self report (IDS-SR) will be completed at each visit.
| score on a scale | Ketamine | Midazolam |
|---|---|---|
| Inventory of Depressive Symptomatology (IDS) Self Report Score | 18.09 ± 2.2 | 16.44 ± 2.4 |
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
| Days to event | Ketamine | Midazolam |
|---|---|---|
| Male | NA ± NA | NA ± NA |
| Female | 74.15 ± 4.5 | 39.36 ± 1.8 |
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
| Days to event | Ketamine | Midazolam |
|---|---|---|
| Hispanic or Latino | 50 ± NA | 40.75 ± .3 |
| Not Hispanic or Latino | 75.18 ± 4.8 | 12 ± NA |
The primary outcome is number of days from the beginning of the study until the first suicidal event. A suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. Mean (Standard Error) days to event was estimated by Kaplan-Meier survival curves.
| Days to event | Ketamine | Midazolam |
|---|---|---|
| American Indian or Alaska Native American Indian or Alaska Native | NA ± NA | NA ± NA |
| Asian | NA ± NA | — |
| Native Hawaiian or Other Pacific Islander | NA ± NA | — |
| Black or African American | 25 ± NA | NA ± NA |
| White | 73.76 ± 4.7 | 39.18 ± 2.0 |
| Unknown or not reported | NA ± NA | NA ± NA |
Collected over Adverse Events were assessed for up to 14 weeks (from the time of informed consent until participant's exit from the study).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketamine | 0/28 (0%) | 5/28 (17.9%) | 28/28 (100%) |
| Midazolam | 0/22 (0%) | 7/22 (31.8%) | 22/22 (100%) |
| Event | Ketamine | Midazolam |
|---|---|---|
| Suicide AttemptPsychiatric disorders | 5/28 | 5/22 |
| Active Suicidal IdeationPsychiatric disorders | 0/28 | 4/22 |
| Suicidal IdeationPsychiatric disorders | 1/28 | 1/22 |
| Sexually inappropriate behaviorPsychiatric disorders | 0/28 | 1/22 |
| Self injurious behavior without suicidal intentPsychiatric disorders | 0/28 | 1/22 |
| Eating DisorderPsychiatric disorders | 1/28 | 0/22 |
| Event | Ketamine | Midazolam |
|---|---|---|
| Perceptual disturbancePsychiatric disorders | 26/28 | 5/22 |
| Time perception alteredPsychiatric disorders | 24/28 | 7/22 |
| DepersonalizationPsychiatric disorders | 23/28 | 2/22 |
| TirednessGeneral disorders | 17/28 | 14/22 |
| DizzinessNervous system disorders | 16/28 | 3/22 |
| Numbness mouthNervous system disorders | 16/28 | 1/22 |
| Blurry visionNervous system disorders | 15/28 | 2/22 |
| NauseuaGastrointestinal disorders | 11/28 | 7/22 |
| SedationNervous system disorders | 10/28 | 1/22 |
| HeadacheNervous system disorders | 8/28 | 7/22 |
| Age, Customized(Participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| 13-14 years | 9 | 8 | 17 |
| 15-17 years | 18 | 12 | 30 |
| 18 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Female | 22 | 19 | 41 |
| Male | 6 | 3 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 16 |
| Not Hispanic or Latino | 20 | 14 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 3 | 4 |
| White | 18 | 14 | 32 |
| More than one race | 3 | 3 | 6 |
| Unknown or Not Reported | 2 | 1 | 3 |
| CHRT-SR(units on a scale) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Mean | 33.04 ± 11.4 | 27.00 ± 12.6 | 30.38 ± 12.2 |
| IDS-SR(units on a scale) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Mean | 34.46 ± 11.6 | 32.50 ± 12.2 | 33.60 ± 11.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Jul 2025, 32 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Midazolam
University of Texas Southwestern Medical Center →